Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics ( (ATHE) ) has shared an announcement.
On January 22, 2025, Alterity Therapeutics announced a new application for the quotation of 95,238 ordinary fully paid securities on the Australian Securities Exchange (ASX), resulting from the conversion of options. This move reflects the company’s ongoing efforts to manage its capital structure and potentially enhance its financial flexibility. By increasing its quoted securities, Alterity aims to strengthen its market position and create additional value for stakeholders.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise within the biotechnology sector, focusing on therapeutic solutions for neurodegenerative diseases. The company is known for its innovative approaches to treating disorders such as Parkinson’s disease and Alzheimer’s, striving to make significant advancements in this challenging area of healthcare.
YTD Price Performance: -6.43%
Average Trading Volume: 70,265
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $29.98M
Learn more about ATHE stock on TipRanks’ Stock Analysis page.
